Q-omics provides the consensus-scored RNF186 profile across patient tissues and cancer cell-line models. RNF186 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF186 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, RNF186 RNA expression shows 11,290 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, KIRP, and ESCA as cancer lineages where RNF186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF186 survival associations across molecular data types. RNF186 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF186 RNA expression–survival associations across cancer types. High RNF186 expression shows unfavorable associations in GBM and LIHC, but favorable associations in KIRC, HNSC, UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF186 RNA expression.
This table summarizes RNF186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNF186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF186 shows lower tumor expression in KIRP, KICH, COAD and BRCA and higher tumor expression in LUAD and KIRC. The KIRP box plot shows higher RNF186 RNA expression in normal versus tumor tissue (log2 FC = −3.593, t-test p < 0.001).
This table shows molecular features associated with RNF186 in patient tissues and cancer cell lines. In patient samples, RNF186 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF186 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
